Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 50 years old.
- You must have a diagnosis of neovascular (wet) age-related macular degeneration in the study eye, confirmed by a reading center.
- Your vision in the study eye must be between 20/640 and 20/25 (approximately 10 to 83 letters on an eye chart).
- Your vision in the other eye must be at least 20/200 (approximately 34 letters or better).
- You must have received anti-VEGF treatment (like Eylea, Lucentis, or Avastin) in the study eye recently and have shown improvement with it.
- You must be able to follow study procedures and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.